Payers Must Brace For Coming Wave Of Cell And Gene Therapies

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.

Amazing, perfect wave - Image

When cell and gene therapies were coming as one at a time, initially for rare diseases, the impact on payers could be minimized. But now that a big wave of regenerative medicines for a wider array of diseases is hitting the commercial market, they could have a significant impact on the bottom line, companies acknowledged during the Alliance for Regenerative Medicine's (ARM's) recent Cell and Gene Meeting on the Mesa.

Given the complicated nature of these products, cell and gene therapy developers emphasized the importance of engaging with payers early...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Gene Therapies

More from Advanced Therapies